Synaffix B.V. and Hummingbird Bioscience have entered right into a licensing settlement that can allow Hummingbird Bio to develop a subsequent era antibody drug conjugate (ADC) program utilizing Synaffix expertise.
Synaffix is a biotechnology firm centered on commercializing its clinical-stage platform expertise for the event of ADCs.
Hummingbird Bio is a data-driven precision biotherapeutics firm utilizing its rational antibody discovery (RAD) platform to find and engineer antibodies in opposition to optimum but elusive epitopes to unlock novel mechanisms of motion.
Below the phrases of the settlement, Synaffix can be eligible to obtain as much as $150 million, together with upfront and milestone funds, plus royalties on internet gross sales. For the goal license, Hummingbird Bio is granted rights to make the most of Synaffix proprietary ADC applied sciences GlycoConnect and HydraSpace, together with choose toxSYN linker-payloads.
Peter van de Sande, CEO of Synaffix, stated: “We’re happy to as soon as once more be capable to strengthen a companion’s pipeline with our modern ADC applied sciences. By combining our cutting-edge ADC expertise platform with Hummingbird Bio’s next-generation portfolio of precision therapeutics we are able to additional contribute in direction of the transformation of most cancers remedy.”
“Hummingbird Bio’s RAD platform generates excessive affinity antibodies in opposition to distinctive epitopes on arduous targets, probably unlocking novel mechanisms of motion. We imagine that, by combining Synaffix’s ADC applied sciences with our antibodies, now we have the potential to create best-in-class ADCs,” stated Piers Ingram, CEO and co-founder of Hummingbird Bio.
“We’re excited by the potential of this partnership and stay up for sharing further updates on our ADC efforts all through 2023.”
About Hummingbird Bioscience
The Hummingbird Bioscience mannequin combines computational and methods biology with moist lab drug discovery in a multi-disciplinary, collaborative setting spanning preliminary discovery by way of medical improvement.
The corporate is at present growing two clinical-stage belongings: HMBD-001, a humanized anti-HER3 monoclonal antibody concentrating on a novel epitope on HER3, and HMBD-002, a humanized anti-VISTA IgG4 monoclonal antibody. Each applications are at present in section 1 research.
The Synaffix platform
The Synaffix platform allows a fast timeline to clinic because of the established provide chain of expertise elements. Granted patents overlaying Synaffix’ expertise present end-to-end safety of the manufacturing expertise in addition to the ensuing merchandise by way of a minimum of 2035. The enterprise mannequin of Synaffix is target-specific expertise out-licensing, as exemplified by way of its present offers with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, Macrogenics and Emergence Therapeutics.
The Synaffix ADC expertise platform consists of GlycoConnect, HydraSpace and toxSYN applied sciences. These applied sciences are aimed toward enabling best-in-class ADCs from any antibody, with considerably enhanced efficacy and tolerability.
GlycoConnect is a clinical-stage conjugation expertise that exploits the native antibody glycan for site-specific and steady payload attachment and is tunable to DAR1, DAR2 or DAR4 codecs. HydraSpace is a clinical-stage compact and extremely polar spacer expertise designed to additional improve therapeutic index, notably with hydrophobic payloads. toxSYN is a linker-payload platform that spans key, validated MOAs for ADC product improvement, together with SYNtecan E and SYNeamicin G, amongst different linker-payloads.
The mix of those three applied sciences supplies builders with a “one cease” and easy-to-use ADC expertise platform, permitting any antibody developer to develop its personal proprietary ADC and any ADC developer to develop its pipeline additional and enhance its aggressive place.